Why the study?
Many DLBCL patients have a poor prognosis and those treated with doxorubicin face cardiac failure risks, while estrogen binding to ERβ shows antitumor and cardioprotective potential.
Does silibinin reduce tumor growth and prevent doxorubicin-induced cardiotoxicity in preclinical models of DLBCL?
Does silibinin reduce tumor growth and prevent doxorubicin-induced cardiotoxicity in preclinical models of DLBCL?
Silibinin demonstrates dual potential as an anti-tumor agent for DLBCL and a cardioprotectant against doxorubicin toxicity in preclinical models.
Answers are grounded in this paper and cite their sources.
Preclinical findings should not change practice; leaves open whether silibinin can pair DLBCL control with doxorubicin cardioprotection.
BACKGROUND/AIM: About 40% of patients with diffuse large cell lymphoma (DLBCL) still have a poor prognosis. Additionally, DLBCL patients treated with doxorubicin are at risk of cardiac failure. Growing evidence suggests an antitumor and cardioprotective activity exerted by estrogen via its binding to estrogen receptor (ER) β. The aim of this study was to evaluate the anticancer activity of the phytoestrogen silibinin, an ERβ selective agonist, on DLBCL growth, and its potential cardioprotective effect. MATERIALS AND METHODS: DLBCL cell lines SUDHL-8, SUDHL-6, and RIVA were used. The anti-tumor activity of silibinin was also evaluated in vivo in NOD/SCID/IL2Rg-/- (NSG) xenografted mice. AC16 human ventricular cardiomyocytes were used to investigate the cardioprotective effects of silibinin. RESULTS: In vitro silibinin induced apoptosis and autophagy, and blocked tumor cell proliferation, also protecting AC16 cardiomyocytes from doxorubicin-induced toxicity. In vivo silibinin induced cell death and autophagy, and reduced tumor volume. CONCLUSION: Silibinin represents a promising therapeutic tool.
No takes yet. Share an insight, caveat, or question.
Ortona et al. (2022) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: